DALLAS, March 4, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Advanced Cell Technology Inc. (OTCBB:ACTC). The report includes financial, comparative and investment analysis, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.investorsoup.com/lp/ACTC
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup">www.twitter.com/investorsoup
Advanced Cell Technology Inc. (ACTC) is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the field of regenerative medicine. The Company has acquired, developed and maintain a portfolio of patents and patent applications that form the base for its research and development efforts in the area of embryonic and adult stem cell research. The Company's technology base, in combination with its know-how, provides an advantage and will facilitate the successful development and commercialization of products for use in the treatment of an array of chronic degenerative diseases and in regenerative repair of acute disease, such as trauma, myocardial infarction and burns. The Company's embryonic stem (ES) cell research programs are divided into three core categories: cellular reprogramming, reduced complexity program and stem cell differentiation.
Message Board Search for ACTC: http://www.boardcentral.com/boards/ACTC
In the report, the analyst notes:
"Revenue for the three months ended September 30, 2009, and 2008, was $248,141 and $242,195, respectively, which represents an increase of $5,946. These amounts relate primarily to license fees and royalties collected that are being amortized over the period of the license granted, and are therefore typically consistent between periods. The increase in revenue during the three months ended September 30, 2009, was due to more new licenses being granted during the year as compared to the three months ended September 30, 2008.
"ACTC this week announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's MA09-hRPE cells for use in the treatment of Stargardt's Macular Dystrophy (SMD)."
To read the entire report visit: http://www.investorsoup.com/lp/ACTC
See what investors say about ACTC at penny stock forum
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit www.InvestorSoup.com/">http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither InvestorSoup nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.